Statistical interpretation of CA125 and Bcl-2 in serum of patients with late stage ovarian cancer.
OBJECTIVE
The present study was conducted to investigate the sensitivity, specificity, predictive values and accuracy of serum CA125 and Bcl-2 levels and their combination in advanced epithelial ovarian cancer patients.


METHODS
Healthy controls (n = 117) with no gynecologic problems and patients with ovarian carcinoma (n = 117), pathologically verified, consecutively admitted to the Istanbul University, Oncology Institute during a one-year period were investigated. Serum Bcl-2 and CA125 were determined by using enzyme linked immunosorbent assay method.


RESULTS
The serum bcl-2 and CA125 levels were significantly higher in patients with ovarian cancer than in the control group (P < 0.001). The diagnostic sensitivity and specificity, predictive values and accuracies were calculated for each marker and their combination.


CONCLUSIONS
The best result was achieved with the combination of CA125-bcl-2. This combination fulfills the need of diagnosis of ovarian carcinoma for the best sensitivity and specificity.
Camlica
Hakan
H
Department of Preventive Oncology, Biostatistics and Epidemiology, Institute of Oncology, University of Istanbul, Istanbul, Turkey. hcamlica@istanbul.edu.tr
Duranyildiz
Derya
D
Tas
Faruk
F
Yasasever
Vildan
V
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood*; D018394:CA-125 Antigen / Q000097:blood*; D016022:Case-Control Studies; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D009375:Neoplasms, Glandular and Epithelial / Q000097:blood* / Q000175:diagnosis; D010051:Ovarian Neoplasms / Q000097:blood* / Q000175:diagnosis; D011379:Prognosis; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000097:blood*; D012680:Sensitivity and Specificity; D055815:Young Adult
D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; D019253:Proto-Oncogene Proteins c-bcl-2